New study eyes Tirzepatide's hidden impact on joints and heart

NCT ID NCT07567378

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 2 times

Summary

This observational study in Mexico will follow 30 adults already taking tirzepatide for conditions like diabetes or obesity. Researchers will use MRI scans of the knees, CT scans of the heart, and body composition tests to see how the drug affects cartilage, heart fat, and overall health. The goal is to understand whether tirzepatide's benefits on joints occur independently of weight loss.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

tirzepatide

What this could lead to

If successful, this study could reveal how tirzepatide impacts joint health and heart fat, potentially guiding future treatments for arthritis and heart disease.

What could go wrong

This is a small, early observational study with only 30 participants, so results may not apply widely. It does not test tirzepatide directly, only observes people already taking it.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEART FAILURE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

abdominal obesity-metabolic syndrome arthropathy atrial fibrillation coronary artery disorder diabetes mellitus heart failure metabolic dysfunction-associated steatotic liver disease metabolic syndrome X Obesity obesity disorder osteoarthritis osteoarthritis, knee pericardium disorder psoriatic arthritis Sarcopenia type 2 diabetes mellitus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

Locations

  • IMSS Clínica Río Magdalena

    Mexico City, Mexico City, 01090, Mexico

    Contact Phone: •••-•••-•••• Email: •••••@•••••